Hepatic Arterial Complications in Liver Transplant Recipients Treated with Pretransplantation Chemoembolization for Hepatocellular Carcinoma

Richard, Howard M.; Silberzweig, James E.; Mitty, Harold A.; Lou, Wenjie; Ahn, Jae-Sung; Cooper, John N.

doi:10.1148/radiology.214.3.r00mr31775

Cited by 52 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrosis, thrombosis and aneurysm were only seen in Group 1, which indicated that pre-TACE might weaken and do harm to HA wall. This result was similar to previous reports [16,17], which showed that pre-TACE for HCC might lead to a higher incidence of radiological and histological injury in HA. Patients in Group 1 seemed to have more early hepatic artery complications (< 30 days) compared to Group 2.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience

Yan

et al. 2015

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

“…Although there were 5 OLT recipients in Group 1 and Group 2, respectively, suffered postoperative hepatic artery complications, there was no significant difference between groups. This was similar to Richard et al, which concluded that patients who received pre-TACE were not at increasing risks at developing postoperative HAC [16].…”

Section: Discussionsupporting

confidence: 87%

Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience

Yan

et al. 2015

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…4,107 These studies include use of RFA, 108,109 chemoembolization, 110 and radioembolization as bridge therapies. 111 …”

Section: Hccmentioning

confidence: 99%

Hepatobiliary Cancers

Benson¹,

Abrams²,

Ben‐Josef³

et al. 2009

J Natl Compr Canc Netw

701

129

View full text Add to dashboard Cite

“…There are several recognized complications of TACE, including postembolization syndrome, infection such as abscess and biloma, biliary stricture, hepatic failure, access site injury, hepatic artery (HA) injury, nontarget embolization, and pulmonary embolism . Major complications are reported for approximately 5% of patients with a quoted risk of death of 1% . Very limited data exist on the incidence of biliary and arterial complications after LT among patients subjected to transarterial therapies before LT .…”

mentioning

confidence: 99%

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization

et al. 2014

View full text Add to dashboard Cite

Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down-stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT. The aim of this study was to compare HA and biliary complications in LT recipients with HCC who received transarterial chemoembolization (TACE) before LT with complications in LT recipients with HCC who did not receive TACE before LT. This was a retrospective cohort study of HCC patients at two transplant centers. The prevalence of HA complications (HA thrombosis, stenosis, or pseudoaneurysm) and biliary complications (nonanastomotic stricture, bile leak, and diffuse injury) were compared between patients treated with or without TACE. There were 456 HCC patients with a median age of 61 years (77% were male, and 63% had hepatitis C virus), and 328 (72%) received TACE before LT. The overall prevalence of HA complications was 4.7% in the no-TACE group and 7.9% in the TACE group (P = 0.22). All HA stenosis complications (n = 14) occurred in the TACE group (P = 0.018 versus the no-TACE group). An older donor age and a lower albumin level significantly increased the odds of HA complications. There was a nonstatistically significant increased odds of HA complications in the TACE group versus the no-TACE group according to an adjusted analysis (odds ratio = 2.02, 95% confidence interval = 0.79-5.16, P = 0.14). The overall prevalence of biliary complications was 16.4% in the no-TACE group and 19.8% in the TACE group (P = 0.40). In conclusion, a lower pre-LT albumin level and an older donor age were significantly associated with higher odds of HA complications after LT. TACE was not associated with higher odds of overall HA complications but was associated with a higher prevalence of HA stenosis. Further studies are warranted to confirm the HA stenosis findings and elucidate the pathogenesis.

show abstract

Hepatic Arterial Complications in Liver Transplant Recipients Treated with Pretransplantation Chemoembolization for Hepatocellular Carcinoma

Abstract: Patients who undergo hepatic arterial chemotherapy are not at an increased risk of developing hepatic arterial thrombosis or other hepatic arterial complications after orthotopic liver transplantation.

Cited by 52 publications

References 19 publications

Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience

Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience

Hepatobiliary Cancers

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization

Contact Info

Product

Resources

About